[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjrfSKAS5Co9LWSNsCA3xwafWqXZy3GT1ofseIMOdztI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"University of Waterloo",[4],89,false,10,4,21582,1,72,[14,16,19,22,24,27,29,31],{"name":15,"count":8},"Myopia",{"name":17,"count":18},"Dry Eye",8,{"name":20,"count":21},"Osteoporosis",6,{"name":23,"count":9},"Malnutrition",{"name":25,"count":26},"Keratoconus",3,{"name":28,"count":26},"Ametropia",{"name":30,"count":26},"Glaucoma",{"name":32,"count":26},"Dementia",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07451184","Comparison of Ocular Lubricants in People With Symptoms of Dry Eye","2027-05-23","Propylene glycol 0.6%",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,70,96,119,145,163,186,211,237,255,279,300,325,343,367,390,408,433,458,485,503,521,546],{"intervention":38,"totalTrials":11,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":68},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":11,"soonestReadout":37},[60],{"nctId":35,"briefTitle":36,"status":61,"phases":62,"primaryCompletion":37,"completion":37,"start":63,"enrollment":64,"conditions":65,"interventions":67},"RECRUITING",[44],"2026-02-23",100,[66],"Dry Eye Symptoms",[38],{"trials":69,"activeCount":51},[],{"intervention":71,"totalTrials":11,"cells":72},"Systane Complete",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":94},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT04091581","Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye","COMPLETED",[44],"2020-02-06","2019-11-21",21,[92],"Evaporative Dry Eye",[71],{"trials":95,"activeCount":51},[],{"intervention":97,"totalTrials":11,"cells":98},"Soft contact lens multipurpose disinfection regimen",{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":117},{"trials":100,"activeCount":51},[],{"trials":102,"activeCount":51},[],{"trials":104,"activeCount":51},[],{"trials":106,"activeCount":51},[],{"trials":108,"activeCount":51},[109],{"nctId":110,"briefTitle":111,"status":86,"phases":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT00349063","Contact Lens Wettability",[44],"2005-07",55,[28],[97],{"trials":118,"activeCount":51},[],{"intervention":120,"totalTrials":11,"cells":121},"Optifree RepleniSH Multipurpose Disinfecting Solution",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":143},{"trials":123,"activeCount":51},[],{"trials":125,"activeCount":51},[],{"trials":127,"activeCount":51},[],{"trials":129,"activeCount":51},[],{"trials":131,"activeCount":51},[132],{"nctId":133,"briefTitle":134,"status":86,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT00455455","Corneal and Conjunctival Sensitivity and Staining Study",[44],"2008-12","2007-03",50,[15,140],"Hyperopia",[120,142],"ReNu Multiplus Multipurpose Solution",{"trials":144,"activeCount":51},[],{"intervention":142,"totalTrials":11,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":161},{"trials":148,"activeCount":51},[],{"trials":150,"activeCount":51},[],{"trials":152,"activeCount":51},[],{"trials":154,"activeCount":51},[],{"trials":156,"activeCount":51},[157],{"nctId":133,"briefTitle":134,"status":86,"phases":158,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":159,"interventions":160},[44],[15,140],[120,142],{"trials":162,"activeCount":51},[],{"intervention":164,"totalTrials":11,"cells":165},"Marketed multipurpose disinfection regimen",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":184},{"trials":167,"activeCount":51},[],{"trials":169,"activeCount":51},[],{"trials":171,"activeCount":51},[],{"trials":173,"activeCount":51},[],{"trials":175,"activeCount":51},[176],{"nctId":177,"briefTitle":178,"status":86,"phases":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"NCT00349882","Effects of Contact Lens Care Regimens on the Corneal Epithelium",[44],"2005-06",30,[15],[164],{"trials":185,"activeCount":51},[],{"intervention":187,"totalTrials":11,"cells":188},"Refresh Tears Lubricant Eye Drops",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":209},{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[],{"trials":198,"activeCount":51},[199],{"nctId":200,"briefTitle":201,"status":86,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT01682460","Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients",[44],"2013-04","2012-08",15,[30,207],"Dry Eyes",[187],{"trials":210,"activeCount":51},[],{"intervention":212,"totalTrials":11,"cells":213},"TheraTears® Lubricant Eye Drop",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":235},{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[],{"trials":221,"activeCount":51},[],{"trials":223,"activeCount":51},[224],{"nctId":225,"briefTitle":226,"status":86,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT02014922","A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)",[44],"2014-11","2013-12",33,[232],"Dry Eye Syndromes",[212,234],"TheraTears® preservative-free single-use containers",{"trials":236,"activeCount":51},[],{"intervention":234,"totalTrials":11,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":51},[],{"trials":242,"activeCount":51},[],{"trials":244,"activeCount":51},[],{"trials":246,"activeCount":51},[],{"trials":248,"activeCount":51},[249],{"nctId":225,"briefTitle":226,"status":86,"phases":250,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":251,"interventions":252},[44],[232],[212,234],{"trials":254,"activeCount":51},[],{"intervention":256,"totalTrials":11,"cells":257},"Xiidra",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":277},{"trials":259,"activeCount":51},[],{"trials":261,"activeCount":51},[],{"trials":263,"activeCount":51},[],{"trials":265,"activeCount":51},[],{"trials":267,"activeCount":51},[268],{"nctId":269,"briefTitle":270,"status":86,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT04297618","The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers",[44],"2024-04-18","2021-07-07",45,[17],[256],{"trials":278,"activeCount":51},[],{"intervention":280,"totalTrials":11,"cells":281},"Marketed soft lens multipurpose disinfection regimen",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":298},{"trials":283,"activeCount":51},[],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[],{"trials":291,"activeCount":51},[292],{"nctId":293,"briefTitle":294,"status":86,"phases":295,"start":180,"enrollment":181,"conditions":296,"interventions":297},"NCT00349843","Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort",[44],[15],[280],{"trials":299,"activeCount":51},[],{"intervention":301,"totalTrials":11,"cells":302},"Acetazolamide 250Mg Tab",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":323},{"trials":304,"activeCount":51},[],{"trials":306,"activeCount":51},[],{"trials":308,"activeCount":51},[],{"trials":310,"activeCount":51},[],{"trials":312,"activeCount":51},[313],{"nctId":314,"briefTitle":315,"status":86,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":205,"conditions":319,"interventions":321},"NCT05575180","Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance",[44],"2024-02-22","2023-08-11",[320],"High Altitude Effects",[301,322],"Methazolamide Pill",{"trials":324,"activeCount":51},[],{"intervention":322,"totalTrials":11,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":341},{"trials":328,"activeCount":51},[],{"trials":330,"activeCount":51},[],{"trials":332,"activeCount":51},[],{"trials":334,"activeCount":51},[],{"trials":336,"activeCount":51},[337],{"nctId":314,"briefTitle":315,"status":86,"phases":338,"primaryCompletion":317,"completion":317,"start":318,"enrollment":205,"conditions":339,"interventions":340},[44],[320],[301,322],{"trials":342,"activeCount":51},[],{"intervention":344,"totalTrials":11,"cells":345},"Systane Complete Preservative-Free",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":354,"NA":365},{"trials":347,"activeCount":51},[],{"trials":349,"activeCount":51},[],{"trials":351,"activeCount":51},[],{"trials":353,"activeCount":51},[],{"trials":355,"activeCount":51},[356],{"nctId":357,"briefTitle":358,"status":86,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":8,"conditions":362,"interventions":364},"NCT06966349","Quantifying Ocular Surface Aberrations After Tear Film Interventions",[44],"2026-01-29","2025-06-10",[363],"Tear Film Characteristics",[344],{"trials":366,"activeCount":51},[],{"intervention":368,"totalTrials":11,"cells":369},"ClearCare",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":386,"NA":388},{"trials":371,"activeCount":51},[],{"trials":373,"activeCount":51},[],{"trials":375,"activeCount":51},[],{"trials":377,"activeCount":51},[378],{"nctId":379,"briefTitle":380,"status":86,"phases":381,"primaryCompletion":136,"completion":136,"start":382,"enrollment":181,"conditions":383,"interventions":384},"NCT00520351","Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)",[43],"2007-08",[15],[368,385],"Optifree Replenish",{"trials":387,"activeCount":51},[],{"trials":389,"activeCount":51},[],{"intervention":385,"totalTrials":11,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":404,"NA":406},{"trials":393,"activeCount":51},[],{"trials":395,"activeCount":51},[],{"trials":397,"activeCount":51},[],{"trials":399,"activeCount":51},[400],{"nctId":379,"briefTitle":380,"status":86,"phases":401,"primaryCompletion":136,"completion":136,"start":382,"enrollment":181,"conditions":402,"interventions":403},[43],[15],[368,385],{"trials":405,"activeCount":51},[],{"trials":407,"activeCount":51},[],{"intervention":409,"totalTrials":11,"cells":410},"Timolol maleate 0.5% ophthalmic solution",{"EARLY_PHASE1":411,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":412,"activeCount":51},[413],{"nctId":414,"briefTitle":415,"status":86,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":181,"conditions":420,"interventions":422},"NCT02697318","Evaluation of a New Method for Instilling Eye Drops",[40],"2017-09","2018-01-07","2016-05",[421,30],"Ophthalmic Solutions",[409],{"trials":424,"activeCount":51},[],{"trials":426,"activeCount":51},[],{"trials":428,"activeCount":51},[],{"trials":430,"activeCount":51},[],{"trials":432,"activeCount":51},[],{"intervention":434,"totalTrials":11,"cells":435},"Integrated Nutrition Pathway for Acute Care",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":446},{"trials":437,"activeCount":51},[],{"trials":439,"activeCount":51},[],{"trials":441,"activeCount":51},[],{"trials":443,"activeCount":51},[],{"trials":445,"activeCount":51},[],{"trials":447,"activeCount":51},[448],{"nctId":449,"briefTitle":450,"status":86,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT03391752","More-2-Eat Phase 2: Scaling and Spread of the Integrated Nutrition Pathway for Acute Care",[],"2019-12-30","2019-12-31","2018-05-01",5158,[23],[434],{"intervention":459,"totalTrials":11,"cells":460},"Alcon Opti-Free® RepleniSH® with Supraclens®",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":462,"activeCount":51},[],{"trials":464,"activeCount":51},[],{"trials":466,"activeCount":51},[],{"trials":468,"activeCount":51},[],{"trials":470,"activeCount":51},[],{"trials":472,"activeCount":51},[473],{"nctId":474,"briefTitle":475,"status":86,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT00754338","Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens",[45],"2008-07","2008-09","2008-01",76,[28],[459,483,484],"Alcon Opti-Free® RepleniSH®","B&L ReNu MultiPlus™",{"intervention":483,"totalTrials":11,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":51},[],{"trials":490,"activeCount":51},[],{"trials":492,"activeCount":51},[],{"trials":494,"activeCount":51},[],{"trials":496,"activeCount":51},[],{"trials":498,"activeCount":51},[499],{"nctId":474,"briefTitle":475,"status":86,"phases":500,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":501,"interventions":502},[45],[28],[459,483,484],{"intervention":484,"totalTrials":11,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":506,"activeCount":51},[],{"trials":508,"activeCount":51},[],{"trials":510,"activeCount":51},[],{"trials":512,"activeCount":51},[],{"trials":514,"activeCount":51},[],{"trials":516,"activeCount":51},[517],{"nctId":474,"briefTitle":475,"status":86,"phases":518,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":519,"interventions":520},[45],[28],[459,483,484],{"intervention":522,"totalTrials":11,"cells":523},"0.09% cyclosporine A ophthalmic solution",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":525,"activeCount":51},[],{"trials":527,"activeCount":51},[],{"trials":529,"activeCount":51},[],{"trials":531,"activeCount":51},[],{"trials":533,"activeCount":51},[],{"trials":535,"activeCount":51},[536],{"nctId":537,"briefTitle":538,"status":86,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT05957211","Improving Drop Instillation Comfort of a Cyclosporine A Solution",[45],"2024-02-20","2023-05-19",40,[544],"Dry Eye Disease",[522],{"intervention":547,"totalTrials":11,"cells":548},"Sensitive Eyes® Plus Saline Solution",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":550,"activeCount":51},[],{"trials":552,"activeCount":51},[],{"trials":554,"activeCount":51},[],{"trials":556,"activeCount":51},[],{"trials":558,"activeCount":51},[],{"trials":560,"activeCount":51},[561],{"nctId":562,"briefTitle":563,"status":86,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":569},"NCT03987230","Comfort Associated With The Use Of Eyelid Cleansing Products Available For The Management Of Demodex Folliculorum",[45],"2019-06-18","2019-05-29",17,[17],[547]]